Press releases::



CreaGen Biosciences Acquires Prime Organics Catalogue Business
May 28, 2014, 08:00 AM EST(PressRelease)    by Creagen

CreaGen positions itself for further growth by expanding its current products' business to better meet the growing demands of the industry to obtain difficult to find and make organic and organometallic compounds.

WOBURN, MA -- CreaGen Biosciences is a specialty drug discovery chemistry service company ("CreaGen"), today announced its next step in meeting the growing demands of the drug discovery industry by acquiring Prime Organics' Catalogue Business. Prime Organics closed its doors after almost 20 years of business this May. Acquiring Prime's Catalogue Business, demonstrates CreaGen's continued evolution to respond to the demands of the industry in turn response to the industry's need to find it extremely challenging to obtain difficult to find and complex organic and organometallic compounds to make. CreaGen will continue to provide their clients their full range of drug discovery chemistry expertise. more...


Customized Chemistry Services CRO, CreaGen Biosciences, Hails New Economical FTE Rates
Posted December 28th, 2013 by Shelley Amster
December 29, 2013 (PressRelease) – Creagen Biosciences hails the success of its 10 year world-class services organization, is pleased to announce a competitive discounted rate for all future projects of 5 FTEs or greater during Q1 2014. "This special offer is our way of saying thanks to all our loyal patrons that have supported us during our first 10 years," commented, Raj Rajur, CEO, President and Founder, CreaGen Biosciences." more...


CreaGen Biosciences and ProXyChem Join Forces to Provide Comprehensive Structure-Based Drug Design Services to Life Science Companies

WOBURN and Weston, Mass., May 6, 2008 – CreaGen Biosciences, Inc. and ProXyChem, LLC announced today that the two companies have entered into an agreement to combine their expertise in offering comprehensive Structure-Based Drug Design (SBDD) and lead optimization services. more...


AMPK Activator Licensing Deal Highlights Successful Collaboration between Boston-based Mercury Therapeutics and CreaGen Biosciences

BOSTON--(BUSINESS WIRE)--The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

For the past three years, Mercury has partnered with CreaGen for medicinal chemistry-based outsourcing of their lead generation program seeking to develop small molecule activators of AMP activated protein kinase. Novel AMPK activators hold promise for the treatment of type 2 diabetes, cardiovascular disease, and cancer. more...
  CreaGen Inc. makes into the 2018 list of major players in CRO industry   more...
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.